Clinical trial
Double Blind Placebo Controlled Dose Ranging Study of the Efficacy and Safety of SSR149744C 300 or 600 mg for the Conversion of Atrial Fibrillation / Flutter
NCT00232310 is registered in ClinicalTrials.gov with Sanofi as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Double Blind Placebo Controlled Dose Ranging Study of the Efficacy and Safety of SSR149744C 300 or 600 mg for the Conversion of Atrial Fibrillation / Flutter
- Lead sponsor
- Sanofi
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- October 31, 2005
- Completion date
- April 30, 2006
- Enrollment
- 150 (actual)
- Sites
- 9
Conditions
As the registry lists them; a condition with its own page is linked.